Since adjuvant CDK4/6 inhibitors (eg, abemaciclib) improve survival of luminal breast cancer at high risk, without ALND makes revealing four or more lymph nodes metastases impossible, which results in these patients not meeting the criteria of adjuvant CDK4/6 inhibitors therapy (41). Here, CDK4 is linked to breast carcinoma.